Phase 1b - The first Parkinson’s patient has been dosed in a Phase 1 clinical trial that is testing IkT-148009

The first Parkinson’s patient has been dosed in a Phase 1 clinical trial that is testing IkT-148009, an investigational oral therapy being developed by Inhibikase Therapeutics to slow or stop disease progression.

“We are pleased to begin dosing patients in our Phase 1b study,” Milton Werner, PhD, Inhibikase‘s president and CEO, said in a press release.

parkinsonsnewstoday.com/202...

[1rocketman]

Looks promising. Thank you for sharing.

[Hidden]

It's moving to a Phase 2 randomized, double-blind, 12-week dosing trial assessing safety & tolerability in untreated

inhibikase.com/news/press-r...